This segment focuses on the development and commercialization of advanced endovascular solutions for the treatment of aortic aneurysms and dissections. Research and development efforts are directed towards creating minimally invasive stent-graft systems that offer improved durability, precise deployment, and enhanced patient outcomes. Technologies employed include advanced biocompatible materials, innovative stent designs, and sophisticated delivery systems. The segment addresses both abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA), aiming to reduce the risks associated with open surgical repair. Clinical trials and post-market studies are conducted to validate the safety and efficacy of these devices, ensuring regulatory compliance and optimal patient care. Future opportunities include expanding the product portfolio to address complex aortic anatomies and developing personalized treatment strategies.

This segment is dedicated to providing innovative medical devices for the treatment of peripheral artery disease (PAD). The focus is on developing and refining balloon dilatation catheters, including PTA (Percutaneous Transluminal Angioplasty) balloons, to restore blood flow in narrowed or blocked peripheral arteries. R&D activities involve the exploration of new materials and coatings to enhance the deliverability and performance of these catheters, minimizing vessel trauma and improving long-term patency. The segment addresses a wide range of PAD indications, from simple lesions to complex, calcified blockages. Clinical studies are conducted to evaluate the safety and effectiveness of these devices in diverse patient populations. Future growth potential lies in the development of drug-coated balloons (DCB) and other advanced technologies to reduce restenosis and improve outcomes for patients with PAD.